LIP
VTGN icon

Lighthouse Investment Partners’s VistaGen Therapeutics VTGN Stock Holding History

Lighthouse Investment Partners’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-20,580
Closed -$13.6K – 1091
2025
Q4 		$13.6K Buy
+20,580
New +$74.3K ﹤0.01% 862

Other funds holding VTGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Lighthouse Investment Partners's VTGN Position: Q1 2026 in Review

Lighthouse Investment Partners sold out of VistaGen Therapeutics (VTGN) in Q1 2026, closing a stake of 20,580 shares — an estimated $13.6K sold.

Lighthouse Investment Partners first reported a position in VTGN in Q4 2025 and held it in 1 quarter. The position peaked at $13.6K in Q4 2025. 56 funds tracked by Wall St. Rank hold VTGN as of Q1 2026.

  • Lighthouse Investment Partners reported no remaining VistaGen Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Lighthouse Investment Partners sold 20,580 VistaGen Therapeutics shares in Q1 2026, an estimated $13.6K.
  • Lighthouse Investment Partners first reported a position in VistaGen Therapeutics in Q4 2025 and held it in 1 quarter.
  • Lighthouse Investment Partners's VistaGen Therapeutics position peaked at $13.6K in Q4 2025.
  • 56 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2026.

Based on Lighthouse Investment Partners's 13F filing for Q1 2026, filed 14 May 2026.